ATE79900T1 - Tierzellenkultur. - Google Patents

Tierzellenkultur.

Info

Publication number
ATE79900T1
ATE79900T1 AT86904268T AT86904268T ATE79900T1 AT E79900 T1 ATE79900 T1 AT E79900T1 AT 86904268 T AT86904268 T AT 86904268T AT 86904268 T AT86904268 T AT 86904268T AT E79900 T1 ATE79900 T1 AT E79900T1
Authority
AT
Austria
Prior art keywords
culture
cells
cell culture
animal cell
culturing
Prior art date
Application number
AT86904268T
Other languages
English (en)
Inventor
John Robert Birch
Robert Charles Boraston
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10581486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE79900(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of ATE79900T1 publication Critical patent/ATE79900T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT86904268T 1985-06-28 1986-06-30 Tierzellenkultur. ATE79900T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB858516415A GB8516415D0 (en) 1985-06-28 1985-06-28 Culture of animal cells
EP86904268A EP0229809B1 (de) 1985-06-28 1986-06-30 Tierzellenkultur
PCT/GB1986/000383 WO1987000195A1 (en) 1985-06-28 1986-06-30 Animal cell culture

Publications (1)

Publication Number Publication Date
ATE79900T1 true ATE79900T1 (de) 1992-09-15

Family

ID=10581486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86904268T ATE79900T1 (de) 1985-06-28 1986-06-30 Tierzellenkultur.

Country Status (13)

Country Link
EP (1) EP0229809B1 (de)
JP (1) JPS62503146A (de)
KR (1) KR920010871B1 (de)
AT (1) ATE79900T1 (de)
AU (1) AU590600B2 (de)
BG (1) BG51050A3 (de)
CA (1) CA1282360C (de)
DE (1) DE3686572T2 (de)
DK (1) DK95687A (de)
GB (2) GB8516415D0 (de)
HU (1) HU197042B (de)
RU (1) RU2015164C1 (de)
WO (1) WO1987000195A1 (de)

Families Citing this family (587)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238891B1 (en) 1987-11-18 2001-05-29 Cetus Oncology Corporation Method of increasing product expression through solute stress
CA1312030C (en) * 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP0435911B1 (de) * 1988-09-23 1996-03-13 Cetus Oncology Corporation Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB9004390D0 (en) * 1990-02-27 1990-04-25 Ici Plc Process
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JP3329387B2 (ja) * 1991-06-17 2002-09-30 インビトロゲン・コーポレーション 培地濃縮物技術
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
ES2107041T3 (es) 1992-06-03 1997-11-16 Genentech Inc Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
GB9215834D0 (en) 1992-07-24 1992-09-09 Celltech Ltd Cell culture
USH1532H (en) * 1993-11-03 1996-05-07 Genetics Institute, Inc. Adaption of mammalian cell lines to high cell densities
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
CA2277266A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
CN100480269C (zh) 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
PT1787999E (pt) 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU9120898A (en) 1997-08-27 1999-03-16 Chiron Corporation Molecular mimetics of meningococcal b epitopes
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
CA2368797C (en) 1999-04-26 2010-08-17 Genentech, Inc. Cell culture process
AU784045B2 (en) 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU783767B2 (en) 1999-10-14 2005-12-01 Takara Bio Usa, Inc. Anthozoa derived chromophores/fluorophores and methods for using the same
EP1757311B1 (de) 1999-12-24 2009-02-11 Genentech, Inc. Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
ATE422369T1 (de) 1999-12-24 2009-02-15 Genentech Inc Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
DE60134956D1 (de) 2000-01-10 2008-09-04 Novartis Vaccines & Diagnostic Gene differentiell experimiert in brudtkrebs
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
EP1297168A2 (de) 2000-07-03 2003-04-02 Gala Design, Inc. Expressionsvektoren
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
JP2004537534A (ja) 2001-06-20 2004-12-16 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物及び方法
DE60224291T2 (de) 2001-08-27 2008-12-11 Genentech, Inc., South San Francisco System zur antikörperexpression und- synthese
EP2311960A3 (de) 2001-08-29 2011-06-01 Genentech, Inc. Bv8-Nukleinsäuren und Polypeptide mit mitogener Aktivität
EP2151244A1 (de) 2001-09-18 2010-02-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003054158A2 (en) 2001-12-19 2003-07-03 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
KR100801388B1 (ko) 2002-01-02 2008-02-05 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
JP2005528905A (ja) 2002-06-07 2005-09-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
WO2004024866A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Protein purification
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP2412725A3 (de) 2003-11-17 2012-04-25 Genentech, Inc. Antikörper gegen CD79b zur Behandlung von Tumoren hämatopoetischen Ursprungs
JP2008504007A (ja) 2003-12-19 2008-02-14 ジェネンテック・インコーポレーテッド 治療薬として有用な一価抗体断片
SI2311873T1 (sl) 2004-01-07 2018-12-31 Novartis Vaccines And Diagnostics, Inc. M-CSF-specifična monoklonska protitelesa in njihova uporaba
US7795041B2 (en) 2004-02-11 2010-09-14 Massachusetts Institute Of Technology Multi-polymer-coated magnetic nanoclusters
DK1736541T3 (da) 2004-03-29 2013-05-06 Galpharma Co Ltd Nyt modificeret galectin 9-protein og anvendelse heraf
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2005100387A1 (en) 2004-04-07 2005-10-27 The University Of Chicago Monomeric red fluorescent proteins
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20060069019A1 (en) 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
DK1771474T3 (da) 2004-07-20 2010-05-31 Genentech Inc Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
DK2322556T3 (en) 2004-09-03 2016-01-25 Genentech Inc Humanized anti-beta7 antagonists, and uses thereof
US7741096B2 (en) 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
DE602006013275D1 (de) 2005-01-07 2010-05-12 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
NZ561681A (en) 2005-03-21 2011-01-28 Virobay Inc Alpha ketoamide compounds as cysteine protease inhibitors
CN101495645B (zh) 2005-03-23 2012-08-22 生物-拉德实验室公司 蛋白纯化方法
ATE515512T1 (de) 2005-05-12 2011-07-15 Zymogenetics Inc Zusammensetzungen und verfahren zur modulierung von immunreaktionen
EP2311876A3 (de) 2005-07-28 2011-04-27 Novartis AG M-CSF-spezifischer monoklonaler Antikörper und Verwendungen davon
EP3181575B1 (de) 2005-08-31 2021-03-17 The Regents of The University of California Zelluläre peptidsequenzbibliotheken (clips) und verfahren zur verwendung davon
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
DK1948798T3 (en) 2005-11-18 2015-07-06 Glenmark Pharmaceuticals Sa The anti-alpha2-integrin antibodies and uses thereof
EP2623516B1 (de) 2005-12-02 2015-07-15 Genentech, Inc. Zusammensetzungen und Verfahren für die Behandlung von Krankheiten und Störungen in Zusammenhang mit der Zytokinsignalisierung, mit Antikörper, die an IL-22 und IL-22R bind.
AU2006338198B2 (en) 2005-12-02 2012-04-26 Genentech, Inc. Binding polypeptides and uses thereof
JP5358187B2 (ja) 2005-12-15 2013-12-04 ジェネンテック， インコーポレイテッド ポリユビキチンを標的とする方法と組成物
EP1973950B1 (de) 2006-01-05 2014-09-17 Genentech, Inc. Anti-ephb4-antikörper sowie verfahren zu deren verwendung
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
EP2389949A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
TWI392684B (zh) 2006-04-05 2013-04-11 亞培生物科技公司 抗體之純化
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
AU2007244683A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
BRPI0711249A2 (pt) 2006-05-30 2012-03-13 Genentech, Inc. Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
AU2007277081B2 (en) * 2006-07-27 2014-02-06 Wyeth Llc High-cell density fed-batch fermentation process for producing recombinant protein
EP2057193B1 (de) 2006-08-04 2013-12-18 Novartis AG Ephb3-spezifischer antikörper und verwendungen davon
PL2059535T3 (pl) 2006-08-18 2014-04-30 Novartis Ag Przeciwciało specyficzne względem PRLR i jego zastosowanie
US8623830B2 (en) 2006-09-12 2014-01-07 Beth Israel Deaconess Medical Center, Inc. Compositions containing α-1-antitrypsin and methods for use
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
RU2460541C2 (ru) 2006-10-27 2012-09-10 Лпат, Инк. Композиции и способы связывания сфингозин-1-фосфата
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
WO2008061019A2 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
WO2008067283A2 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
KR20140119831A (ko) 2006-12-07 2014-10-10 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
WO2008100805A2 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
SI2155248T1 (sl) 2007-04-12 2015-12-31 The Brigham And Women's Hospital, Inc. Ciljanje ABCB5 za zdravljenje raka
WO2008150841A1 (en) 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
MX2009013082A (es) 2007-06-07 2010-01-15 Genentech Inc Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
EP2188302B1 (de) 2007-07-09 2017-11-01 Genentech, Inc. Verhinderung der reduktion der disulfidbindung während der rekombinanten herstellung von polypeptiden
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN111499748A (zh) 2007-07-16 2020-08-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
HRP20131108T1 (hr) 2007-09-05 2014-01-31 Genentech, Inc. Biološki aktivan arginin koji na c-završetku sadrži peptide
JP5496897B2 (ja) 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
AU2008323770B2 (en) 2007-11-07 2014-08-07 Genentech, Inc. Compositions and methods for treatment of microbial disorders
EP2209807A1 (de) 2007-11-08 2010-07-28 Genentech, Inc. Anti-faktor-b-antikörper und ihre verwendungen
WO2009073511A2 (en) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
EP2294087B1 (de) 2008-05-01 2014-05-14 Amgen, Inc. Anti-hepcidin-antikörper und verfahren zu ihrer verwendung
SG190596A1 (en) 2008-05-06 2013-06-28 Genentech Inc Affinity matured crig variants
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
PT3604324T (pt) 2008-08-14 2024-05-10 Genentech Inc Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
JP4883067B2 (ja) 2008-09-29 2012-02-22 株式会社日立プラントテクノロジー 培養装置及び培養方法
RU2520838C2 (ru) 2008-10-20 2014-06-27 Эббви Инк Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
KR20110081862A (ko) 2008-10-22 2011-07-14 제넨테크, 인크. 축삭 변성의 조절
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
EP2346903A1 (de) 2008-11-06 2011-07-27 Glenmark Pharmaceuticals S.A. Behandlung mit anti-alpha2-integrinantikörpern
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
US10080578B2 (en) 2008-12-16 2018-09-25 Nico Corporation Tissue removal device with adjustable delivery sleeve for neurosurgical and spinal surgery applications
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
HRP20150965T1 (hr) 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
CA2766842A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Enhancement of cellular production through mechanotransduction
WO2011011689A2 (en) 2009-07-23 2011-01-27 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
JP2013500993A (ja) 2009-07-31 2013-01-10 ジェネンテック， インコーポレイテッド Ｂｖ８アンタゴニスト又はｇ−ｃｓｆアンタゴニストを用いた腫瘍転移の阻害
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
TW201119677A (en) 2009-10-19 2011-06-16 Genentech Inc Modulators of hepatocyte growth factor activator
KR20170136649A (ko) 2009-10-20 2017-12-11 애브비 인코포레이티드 단백질 ａ 친화성 크로마토그래피를 사용한 항―ｉｌ―１３ 항체의 분리 및 정제
EP3011970A3 (de) 2009-10-22 2016-06-08 F. Hoffmann-La Roche AG Modulation der axondegeneration
MX2012004647A (es) 2009-10-22 2012-06-19 Genentech Inc Anticuerpos antihepsina y metodos para su uso.
MX2012004617A (es) 2009-10-22 2012-05-08 Genentech Inc Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
US8524458B2 (en) 2009-11-09 2013-09-03 Abbvie Inc. Secretory protein biomarkers for high efficiency protein expression
TW201121570A (en) 2009-11-12 2011-07-01 Genentech Inc A method of promoting dendritic spine density
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
WO2011065940A1 (en) 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
AU2010324686B2 (en) 2009-11-30 2016-05-19 Genentech, Inc. Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
KR101989628B1 (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
AU2010336485B2 (en) 2009-12-23 2015-03-26 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
PE20130214A1 (es) 2010-02-23 2013-03-11 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
EP3590966B1 (de) 2010-02-23 2025-03-05 Sanofi Anti-alpha2-integrin-antikörper und deren verwendungen
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
RS57114B1 (sr) 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
BR112012027001A2 (pt) 2010-04-23 2016-07-19 Genentech Inc produção de proteínas heteromultiméricas
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
PL2563906T3 (pl) 2010-04-26 2018-04-30 Novartis Ag Sposób hodowli komórek cho
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
PE20130460A1 (es) 2010-05-03 2013-04-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
CN104777301B (zh) 2010-05-10 2018-04-20 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及流感病毒的奥司他韦易感性的测定
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
BR112012032206A2 (pt) 2010-06-16 2016-10-04 Abbvie Inc comparações de amostras de proteínas
TW201244719A (en) 2010-07-09 2012-11-16 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
CN103314296A (zh) 2010-08-10 2013-09-18 安姆根有限公司 用于检测针对靶抗体的中和抗体的双功能体外靶结合测定
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
EP2618904A1 (de) 2010-09-20 2013-07-31 AbbVie Inc. Reinigung von antikörpern mit simulierter wanderbett-chromatografie
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
JP5868410B2 (ja) 2010-10-08 2016-02-24 シャンハイ クーシン バイオテック カンパニー，リミテッド 再生不良性貧血と関連しているモエシン断片
JP5913326B2 (ja) 2010-10-08 2016-04-27 シャンハイ クーシン バイオテック カンパニー，リミテッド モエシン断片の診断的および治療的使用
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
JP5696220B2 (ja) 2010-10-08 2015-04-08 シャンハイ クーシン バイオテック カンパニー，リミテッド 免疫性血小板減少症を診断するための測定方法及びキット、並びに診断組成物の製造におけるモエシン断片の使用
US9632098B2 (en) 2010-10-08 2017-04-25 Shanghai Kexin Biotech Co., Ltd. Moesin fragments and uses thereof
EP2635601B1 (de) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23-antikörper
JP6296536B2 (ja) 2010-11-05 2018-03-20 メドベット サイエンス ピーティーワイエルティーディーＭｅｄｖｅｔ Ｓｃｉｅｎｃｅ Ｐｔｙ Ｌｔｄ 内皮前駆細胞のマーカーおよびその使用
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US20140066431A1 (en) 2010-11-15 2014-03-06 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
US20140378436A9 (en) 2010-11-24 2014-12-25 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
CN103429261A (zh) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2665822A1 (de) 2011-01-18 2013-11-27 Amgen Inc. Nav1.7-knockout-mäuse und ihre verwendung
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2013140685A (ru) 2011-02-04 2015-03-10 Дженентек, Инк. ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
WO2012122528A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
EP2689250A1 (de) 2011-03-23 2014-01-29 AbbVie Inc. Verfahren und systeme zur analyse von proteinproben
AU2012236304C1 (en) 2011-03-31 2017-01-05 Genentech, Inc. Methods of administering beta7 integrin antagonists
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN108424451B (zh) 2011-06-03 2022-09-09 佐马技术有限公司 对TGF-β具有特异性的抗体
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
KR20140068877A (ko) 2011-08-17 2014-06-09 제넨테크, 인크. 불응성 종양에서의 혈관신생의 억제
HUE065876T2 (hu) 2011-10-11 2024-06-28 Hoffmann La Roche Bispecifikus antitestek javított összeállítása
CN104053670A (zh) 2011-10-31 2014-09-17 百时美施贵宝公司 具有降低的免疫原性的纤连蛋白结合域
HUE047437T2 (hu) 2011-11-16 2020-04-28 Boehringer Ingelheim Int Anti-IL-36R antitestek
US9988611B2 (en) 2011-12-01 2018-06-05 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
RU2639564C2 (ru) 2011-12-16 2017-12-21 Браскем С.А. Модифицированные микроорганизмы и способы получения бутадиена с их применением
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
US20150201588A1 (en) 2012-02-22 2015-07-23 Amgen Inc. Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
PT2841087T (pt) 2012-04-27 2017-11-27 Us Health Antagonistas de fator de crescimento endotelial vascular e métodos para utilização dos mesmos
WO2013165791A1 (en) 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies
TW201348247A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
JP6203838B2 (ja) 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
EP2867254B1 (de) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Verfahren zum herstellen von antikörper-fc-region-konjugaten mit mindestens einer bindungsstelle, die spezifisch an ein target bindet, und verwendungen davon
CN104395340B9 (zh) 2012-06-27 2018-11-30 弗·哈夫曼-拉罗切有限公司 包含至少两个不同靶向实体的定制选择性和多特异性治疗分子的方法及其用途
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
JP6211084B2 (ja) 2012-08-21 2017-10-11 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ ベンゾシクロオクチン化合物およびその使用
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2884368C (en) 2012-10-05 2022-01-18 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2951206A2 (de) 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin-basierte gerüstproteine
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
RS63820B1 (sr) 2013-03-13 2023-01-31 Genzyme Corp Fuzioni prотеini kојi sadrže pdgf i vеgf vеzuјuće dеlоve i метоdе njihоvе upотrеbе
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
RS60534B1 (sr) 2013-03-13 2020-08-31 Hoffmann La Roche Formulacije sa smanjenom oksidacijom
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
CA3113172A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Screen for compound that prevents protein oxidation based on comparison with l-tryptophan
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AU2013384204B2 (en) 2013-03-14 2017-03-16 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
SG11201506497SA (en) 2013-03-15 2015-09-29 Glaxosmithkline Ip No 2 Ltd Use of tricarboxylic acid (tca) intermediates to control ammonia generation in cell culture
JP2016513478A (ja) 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
US10017732B2 (en) 2013-03-15 2018-07-10 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
AU2014241552B2 (en) 2013-03-27 2018-08-16 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
BR112015032554A8 (pt) 2013-06-25 2018-01-23 Sepia Pesquisa E Desenvolvimento moduladores do receptor de bradicinina e seu uso
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
PL3036320T5 (pl) 2013-08-19 2024-06-10 Biogen Ma Inc. Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
US11078464B2 (en) 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
AU2014391422A1 (en) 2013-09-17 2015-12-17 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
BR112016006321B1 (pt) 2013-09-23 2022-11-16 Braskem S.A Enzima engenheirada tendo especificidade de substrato aceto acetil-coa e atividade aceto acetil-coa específica de hidrolase, micro-organismo modificado, e, processo de produção de um ou mais produtos a partir de uma fonte de carbono fermentável
MX375378B (es) 2013-09-27 2025-03-06 Genentech Inc Formulaciones de anticuerpos anti-pdl1.
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
MX384984B (es) 2013-10-10 2025-03-14 Beth Israel Deaconess Medical Ct Inc Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20160272674A1 (en) 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of antibodies
HUE065394T2 (hu) 2013-11-15 2024-05-28 Hoffmann La Roche Vírusok inaktiválására szolgáló eljárások környezetbarát detergensek alkalmazásával
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2014363944B2 (en) 2013-12-09 2020-03-26 Allakos Inc. Anti-Siglec-8 antibodies and methods of use thereof
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
CN112353943A (zh) 2013-12-17 2021-02-12 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
EP3083933B1 (de) 2013-12-20 2026-01-21 Biogen MA Inc. Verwendung von perfusionssaatkulturen zur verbesserung der biopharmazeutischen fed-batch-produktionskapazitäten und der produktqualität
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
KR20160113715A (ko) 2014-01-31 2016-09-30 베링거 인겔하임 인터내셔날 게엠베하 신규한 항-ｂａｆｆ 항체
EP3102197B1 (de) 2014-02-04 2018-08-29 Genentech, Inc. Smoothened-mutant und verfahren zur verwendung davon
DK3110446T3 (da) 2014-02-28 2022-02-28 Allakos Inc Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
US10442851B2 (en) 2014-03-20 2019-10-15 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
CN106795214B (zh) 2014-03-20 2022-09-02 百时美施贵宝公司 稳定化的基于纤连蛋白的支架分子
WO2015148515A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
SI3122799T1 (sl) 2014-03-25 2020-06-30 F. Hoffmann-La Roche Ag Metode priprave poloksamera za uporabo v gojišču za celične kulture
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
CA2939246A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
KR20250165670A (ko) 2014-05-06 2025-11-26 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
DK3149045T3 (da) 2014-05-27 2023-03-06 Academia Sinica Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20220151036A (ko) 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
AU2015267044A1 (en) 2014-05-28 2016-12-15 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
WO2015184327A1 (en) 2014-05-30 2015-12-03 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
HRP20201663T1 (hr) 2014-07-09 2020-12-25 F. Hoffmann - La Roche Ag PRILAGOĐAVANJE pH VRIJEDNOSTI RADI POBOLJŠANJA OPORAVKA BANAKA STANICA USLIJED ODMRZAVANJA
EP3172233B1 (de) 2014-07-22 2019-09-11 Sutro Biopharma, Inc. Anti-cd74-antikörper, zusammensetzungen mit anti-cd74-antikörpern und verfahren zur verwendung von anti-cd74-antikörpern
EP3708679A1 (de) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH In der behandlung von il-23a-assoziierten erkrankungen nützlicher biomarker
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
WO2016061141A1 (en) 2014-10-13 2016-04-21 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
MX377591B (es) 2014-10-15 2025-03-10 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas.
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
CN107001455B (zh) 2014-11-19 2022-03-01 皇家飞利浦有限公司 利用hnl的诊断方法
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
TWI710571B (zh) 2015-01-24 2020-11-21 中央研究院 腫瘤標記及其使用方法
KR102620346B1 (ko) 2015-01-30 2024-01-02 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
HK1244512A1 (zh) 2015-02-04 2018-08-10 健泰科生物技术公司 突变型smoothened及其使用方法
WO2016126638A1 (en) 2015-02-04 2016-08-11 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
MX2017010336A (es) 2015-02-26 2017-12-20 Genentech Inc Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
PT3277821T (pt) 2015-03-31 2019-10-31 Novimmune Sa Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos
CA2981183A1 (en) 2015-04-07 2016-10-13 Greg Lazar Antigen binding complex having agonistic activity and methods of use
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
EP3685856A1 (de) 2015-04-14 2020-07-29 Boehringer Ingelheim International GmbH Verfahren zur behandlung von krankheiten
CN116063543A (zh) 2015-04-24 2023-05-05 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
EP3291836A4 (de) 2015-05-06 2018-11-14 Janssen Biotech, Inc. Bispezifische bindemittel für prostataspezifisches membranantigen (psma) und verwendungen davon
EP3763827A1 (de) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1-promotormethylierung bei krebs
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
US11213613B2 (en) 2015-06-12 2022-01-04 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Three-dimensional tissue scaffold with stem cell attracting element and use thereof
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
HK1251493A1 (zh) 2015-06-17 2019-02-01 豪夫迈‧罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
EP3792279A3 (de) 2015-07-29 2021-07-07 Allergan, Inc. Schwere-ketten-antikörper gegen ang-2
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
AU2016304588A1 (en) 2015-08-06 2018-02-15 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP4458417A3 (de) 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Neue anti-pd-1-antikörper
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CA2992788A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
EP3932953A1 (de) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anti-hypusin-antikörper und verwendungen davon
KR20180050339A (ko) 2015-09-04 2018-05-14 오비아이 파머 인코퍼레이티드 글리칸 어레이 및 사용 방법
US20180237542A1 (en) 2015-09-15 2018-08-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
AU2016329001A1 (en) 2015-09-22 2018-03-29 Genentech, Inc. Expression of Fc-containing proteins
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
US10584160B2 (en) 2015-09-23 2020-03-10 Bristol-Myers Squibb Company Glypican-3-binding fibronectin based scaffold molecules
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
BR112018007356A2 (pt) 2015-11-02 2018-10-23 Genentech Inc métodos de produção de formas fucosiladas e não fucosiladas de uma proteína
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EP3390447A1 (de) 2015-12-15 2018-10-24 Amgen Inc. Pacap-antikörper und verwendungen davon
ES3038408T3 (en) 2015-12-30 2025-10-13 Hoffmann La Roche Formulations with reduced degradation of polysorbate
KR20180093078A (ko) 2015-12-30 2018-08-20 제넨테크, 인크. 단백질 제제를 위한 트립토판 유도체의 용도
EP3400246B1 (de) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Verfahren zur behandlung von cea-positiven karzinomen mit pd-1-achsen-bindungsantagonisten und bispezifischen anti-cea/anti-cd3-antikörpern
BR112018015238A2 (pt) 2016-01-27 2018-12-18 Sutro Biopharma Inc conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
EP3408397B1 (de) 2016-01-27 2020-07-15 Just-Evotec Biologics, Inc. Hybrider promoter und verwendungen davon
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
EP4112641A1 (de) 2016-03-15 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Verfahren zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und anti-gpc3-antikörpern
US10822416B2 (en) 2016-03-23 2020-11-03 Mabspace Biosciences (Suzhou) Co., Ltd Anti-PD-L1 antibodies
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20180121786A (ko) 2016-03-29 2018-11-08 오비아이 파머 인코퍼레이티드 항체, 제약 조성물 및 방법
KR20190005873A (ko) 2016-04-15 2019-01-16 앨더 바이오파마슈티컬즈, 인코포레이티드 항-pacap 항체 및 그의 용도
EP3560956A3 (de) 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Verfahren zur behandlung von entzündlichen krankheiten
SG11201809024UA (en) 2016-04-22 2018-11-29 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
SG11201809959PA (en) 2016-05-10 2018-12-28 Genentech Inc Methods of decreasing trisulfide bonds during recombinant production of polypeptides
EA201892796A1 (ru) 2016-06-03 2019-06-28 Янссен Байотек, Инк. Связывающиеся с сывороточным альбумином домены фибронектина типа iii
EP3472197A1 (de) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antikörper mit manipulierten ch2-domänen, zusammensetzungen davon und verfahren zur verwendung davon
BR112018075516A2 (pt) 2016-06-17 2019-10-01 Genentech, Inc. purificação de anticorpos multiespecíficos
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
TWI752988B (zh) 2016-07-27 2022-01-21 台灣浩鼎生技股份有限公司 免疫性/治療性聚醣組合物及其用途
EP3491026A4 (de) 2016-07-29 2020-07-29 OBI Pharma, Inc. Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
JP7088932B2 (ja) 2016-09-14 2022-06-21 ヤンセン バイオテツク，インコーポレーテツド Ｂｃｍａ特異的フィブロネクチンｉｉｉ型ドメインを有するキメラ抗原受容体、及びその使用
EP3515950A4 (de) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. Neuartige anti-pcsk9-antikörper
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3526254A1 (de) 2016-10-12 2019-08-21 Sutro Biopharma, Inc. Anti-folatrezeptor-antikörper, zusammensetzungen mit anti-folatrezeptor-antikörpern und verfahren zur herstellung und verwendung von anti-folatrezeptor-antikörpern
EP4032906A1 (de) 2016-10-14 2022-07-27 Boehringer Ingelheim International GmbH Verfahren zur behandlung von krankheiten
KR102423086B1 (ko) 2016-10-20 2022-07-20 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도
EP3532496A1 (de) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Antikörper gegen ubiquitin c-terminale hydrolase l1 (uch-l1) und gliales fibrilläres saures protein (gfap) und verwandte verfahren
WO2018090052A1 (en) 2016-11-14 2018-05-17 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
CN110290800A (zh) 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
CA3043487A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018156777A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP3596126A4 (de) 2017-03-15 2021-03-03 Tsinghua University Neuartige anti-trkb-antikörper
EP3601350A1 (de) 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Kombinationstherapie gegen il-36r-antikörper
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3618868A4 (de) 2017-05-05 2021-02-24 Allakos Inc. Verfahren und zusammensetzungen zur behandlung von allergischen augenkrankheiten
US20200079850A1 (en) 2017-05-24 2020-03-12 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
JP7280238B2 (ja) 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
SG11202000658PA (en) 2017-07-26 2020-02-27 Forty Seven Inc Anti-sirp-alpha antibodies and related methods
JP7097433B2 (ja) 2017-08-17 2022-07-07 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法
SG11202002310UA (en) 2017-09-18 2020-04-29 Sutro Biopharma Inc Anti- folate receptor alpha antibody conjugates and their uses
US11365254B2 (en) 2017-09-22 2022-06-21 WuXi Biologics Ireland Limited Bispecific CD3/CD19 polypeptide complexes
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
EP3713591A1 (de) 2017-11-20 2020-09-30 Just-Evotec Biologics, Inc. Afliberept-formulierungen mit einem lysinsalz als tonikum und verwendungen davon
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
US20220153871A1 (en) 2018-01-04 2022-05-19 Iconic Therapeutics, Inc. Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods
AR114080A1 (es) 2018-01-12 2020-07-22 Amgen Inc Anticuerpos pac1 y sus usos
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
US11667949B2 (en) 2018-02-15 2023-06-06 The Trustees Of Princeton University Reporter construct and biosensor for interferon second messenger 2-5A
EP3765522A4 (de) 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin-18.2-antikörper
US12202894B2 (en) 2018-03-20 2025-01-21 WuXi Biologics Ireland Limited Anti-TIM-3 antibodies
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
CA3094098A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
US11993658B2 (en) 2018-03-26 2024-05-28 Sutro Biopharma, Inc. Anti-BCMA antibodies and treatment methods
SG11202009542PA (en) 2018-03-29 2020-10-29 Genentech Inc Modulating lactogenic activity in mammalian cells
KR102876940B1 (ko) 2018-03-30 2025-10-24 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
WO2019195185A1 (en) 2018-04-02 2019-10-10 Amgen Inc. Erenumab compositions and uses thereof
EP3774916A2 (de) 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin-33-wirkstoffe und -zusammensetzungen und verfahren zur herstellung und verwendung davon
EP3788071A1 (de) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose, prävention und behandlung von epstein-barr-virusinfektion
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
BR112020023118A2 (pt) 2018-05-14 2021-04-13 Werewolf Therapeutics, Inc. Polipeptídeos de interleucina 12 ativáveis e métodos de uso destes
MY205645A (en) 2018-06-23 2024-11-02 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CA3101469A1 (en) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
MX2019012869A (es) 2018-07-13 2020-01-23 Alector Llc Anticuerpos anti-sortilina y metodos para su uso.
KR102140531B1 (ko) 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
BR112021002130A2 (pt) 2018-08-08 2021-05-04 Genentech, Inc. formulação líquida, artigo de fabricação ou kit e método para reduzir a oxidação de um polipeptídeo
EP3852811A1 (de) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Kombinationstherapien mit anti-folat-rezeptor-antikörper-konjugaten
US20210355215A1 (en) 2018-09-21 2021-11-18 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
JP7475336B2 (ja) 2018-09-21 2024-04-26 ジェネンテック， インコーポレイテッド トリプルネガティブ乳癌のための診断方法
WO2020068557A1 (en) 2018-09-25 2020-04-02 BioLegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
EP3856764A4 (de) 2018-09-27 2022-11-02 Xilio Development, Inc. Maskierte cytokin-polypeptide
EA202190609A1 (ru) 2018-09-27 2021-08-17 Тизона Терапьютикс Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EP3870614A1 (de) 2018-10-23 2021-09-01 GlyCardial Diagnostics, S.L. Antikörper spezifisch für glykosyliertes apoj und verwendungen davon
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
KR20210098976A (ko) 2018-12-04 2021-08-11 카탈렌트 파마 솔루션즈, 엘엘씨 단백질 제조를 위한 벡터
KR102910209B1 (ko) 2018-12-21 2026-01-09 제넨테크, 인크. 세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
CN113490687A (zh) 2018-12-26 2021-10-08 西利欧发展公司 抗ctla4抗体和其使用方法
CA3124515A1 (en) 2019-01-23 2020-07-30 Genentech, Inc. Methods of producing multimeric proteins in eukaryotic host cells
EP3924458A1 (de) 2019-02-15 2021-12-22 Just-Evotec Biologics, Inc. Automatisierte bioherstellungssysteme, anlagen und prozesse
MX2021010783A (es) 2019-03-08 2021-09-30 Boehringer Ingelheim Int Formulaciones de anticuerpo anti-il-36r.
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
EP3962946A1 (de) 2019-05-03 2022-03-09 Celgene Corporation Anti-bcma-antikörper-konjugat, zusammensetzungen damit und verfahren zu deren herstellung und verwendung
EP3962951A1 (de) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma-antikörper-konjugate
AU2020268399B2 (en) 2019-05-09 2025-01-23 Genentech, Inc. Methods of making antibodies
CA3137377A1 (en) 2019-05-09 2020-11-12 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating eye or ocular diseases
WO2020232305A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
JP7600218B2 (ja) 2019-05-24 2024-12-16 サンヨウ バイオファーマシューティカルズ カンパニー リミテッド 新規なｃｌｄｎ１８．２結合分子
SG11202112926YA (en) 2019-05-30 2021-12-30 Amgen Inc Engineering the hinge region to drive antibody dimerization
US12534465B2 (en) 2019-06-10 2026-01-27 Sutro Biopharma, Inc. 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
JP2022536800A (ja) 2019-06-17 2022-08-18 ストロ バイオファーマ インコーポレーテッド Ｔｏｌｌ様受容体（ｔｌｒ）７／８アゴニストとしての１－（４－（アミノメチル）ベンジル）－２－ブチル－２ｈ－ピラゾロ［３，４－ｃ］キノリン－４－アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
AU2020304671A1 (en) 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
JPWO2021010326A1 (de) 2019-07-12 2021-01-21
EP4004044A1 (de) 2019-07-24 2022-06-01 H. Lundbeck A/S Anti-mglur5-antikörper und verwendungen davon
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
EP4054590A1 (de) 2019-11-04 2022-09-14 Amgen Inc. Verfahren zur behandlung von leukämie
MX2022005566A (es) 2019-11-08 2022-07-19 Amgen Inc Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
EP4058471A1 (de) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Aktivierbare cytokin-polypeptide und verfahren zur verwendung davon
AU2020386005A1 (en) 2019-11-19 2022-05-26 Amgen Inc. Novel multispecific antibody format
JP7703541B2 (ja) 2019-12-18 2025-07-07 アロ・バイオセラピューティクス・カンパニー 血清アルブミン結合性フィブロネクチンｉｉｉ型ドメインおよびその使用
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
WO2021146383A1 (en) 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
JP2023515463A (ja) 2020-02-21 2023-04-13 ブラスケム エス．エー． 酵母におけるエタノールおよび１つまたは複数の共生産物の生産方法
US20230340114A1 (en) 2020-03-12 2023-10-26 Immune-Onc Therapeutics, Inc. Novel anti-lilrb4 antibodies and derivative products
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
EP4127153A2 (de) 2020-03-26 2023-02-08 Genentech, Inc. Modifizierte säugetierzellen mit reduzierten wirtszellproteinen
WO2021211493A1 (en) 2020-04-15 2021-10-21 Genentech, Inc. Copper loss mitigation
JP2023522417A (ja) 2020-04-24 2023-05-30 エフ． ホフマン－ラ ロシュ アーゲー スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
JP7512433B2 (ja) 2020-05-26 2024-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｄ－１抗体
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
JP2023533217A (ja) 2020-06-24 2023-08-02 ジェネンテック， インコーポレイテッド アポトーシス耐性細胞株
CA3191710A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
JP2023539201A (ja) 2020-08-28 2023-09-13 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
CA3194771A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
EP4225786A2 (de) 2020-10-07 2023-08-16 Amgen Inc. Rationale auswahl von bausteinen zur anordnung multispezifischer antikörper
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
AU2021379598A1 (en) 2020-11-10 2023-06-08 Amgen Inc. Novel linkers of multispecific antigen binding domains
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
CN112538458B (zh) 2020-11-26 2025-10-31 北京孟眸生物科技有限公司 用于重编程细胞的方法
CN117043181A (zh) 2020-12-18 2023-11-10 基尼科萨制药有限公司 蛋白质组合物以及其产生和使用方法
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
JP2024505524A (ja) 2021-01-29 2024-02-06 メルク・シャープ・アンド・ドーム・エルエルシー プログラム死受容体１（ｐｄ－１）抗体の組成物及びその組成物を得る方法
EP4288457A2 (de) 2021-02-05 2023-12-13 Boehringer Ingelheim International GmbH Anti-il1rap-antikörper
US20220340662A1 (en) 2021-03-01 2022-10-27 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301467A1 (de) 2021-03-01 2024-01-10 Xilio Development, Inc. Kombination von ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
US20240392004A1 (en) 2021-03-10 2024-11-28 Immunowake Inc. Immunomodulatory molecules and uses thereof
EP4326855A1 (de) 2021-04-19 2024-02-28 Genentech, Inc. Modifizierte säugerzellen
CN117651714A (zh) 2021-04-20 2024-03-05 美国安进公司 多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
JP2024517418A (ja) 2021-04-23 2024-04-22 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体組成物及びその使用
EP4332120A1 (de) 2021-04-26 2024-03-06 Xuanzhu Biopharmaceutical Co., Ltd. Bispezifisches antikörper-wirkstoff-konjugat
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
US20240366777A1 (en) 2021-05-19 2024-11-07 Sutro Biopharma, Inc. Anti-folate receptor conjugate combination therapy with bevacizumab
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
CN117940144A (zh) 2021-05-27 2024-04-26 R.P.谢勒技术有限责任公司 控制含甲酰甘氨酸的多肽的切割的方法
WO2023287707A1 (en) 2021-07-15 2023-01-19 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
CN118284623A (zh) 2021-08-23 2024-07-02 伊莫尼塔斯治疗公司 抗cd161抗体及其用途
TW202330613A (zh) 2021-11-12 2023-08-01 美商建南德克公司 使用整聯蛋白β７拮抗劑治療克隆氏病之方法
JP2024543158A (ja) 2021-11-24 2024-11-19 スーチョウ ライト フェリー バイオメッド．カンパニー，リミティド 多重特異性リガンド結合分子及びその用途
US20240408228A1 (en) 2021-12-01 2024-12-12 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
WO2023114897A2 (en) 2021-12-15 2023-06-22 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus
CN118434764A (zh) 2021-12-22 2024-08-02 Cdr生物科技股份有限公司 抗c3抗体及其抗原结合片段及其用于治疗眼疾病的用途
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
EP4476335A2 (de) 2022-02-10 2024-12-18 Amgen Inc. Antikörperproteinproduktexpressionskonstrukte für hochdurchsatzsequenzierung
AU2023232781A1 (en) 2022-03-07 2024-09-26 Ultragenyx Pharmaceutical Inc. Modified batch aav production systems and methods
EP4490177A1 (de) 2022-03-08 2025-01-15 Amgen Inc. Modulares vektorsystem: plattform zur konstruktion von expressionsvektoren der nächsten generation
US20250188495A1 (en) 2022-03-09 2025-06-12 Amgen Inc. Optimized transfection protocol
CN118946583A (zh) 2022-03-21 2024-11-12 美国安进公司 用t细胞接合分子治疗前列腺癌的联合治疗方法
EP4547701A1 (de) 2022-07-01 2025-05-07 Sutro Biopharma, Inc. Il-12-mutanten mit reduzierter toxizität, zusammensetzungen davon und verfahren zur verwendung davon
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
TW202423979A (zh) 2022-08-22 2024-06-16 美商雅博得樂醫療公司 Dll3結合分子及其用途
AR130295A1 (es) 2022-08-24 2024-11-20 Braskem Sa Proceso de recuperación de componentes de bajo punto de ebullición de una corriente de etanol
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024228717A2 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
JP2025535042A (ja) 2022-10-05 2025-10-22 アムジェン インコーポレイテッド Ｔ細胞リダイレクト療法及びアゴニスト抗ｉｌ－２ｒ抗体又はその断片を含む組み合わせ療法
AR130862A1 (es) 2022-10-26 2025-01-29 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates
CN120476149A (zh) 2022-12-23 2025-08-12 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
JP2025542327A (ja) 2022-12-23 2025-12-25 チマゲン・バイオサイエンシズ，リミテッド 新規抗ｇｐｒｃ５ｄ抗体
CN121079327A (zh) 2023-05-12 2025-12-05 基因泰克公司 用于降低抗体粘度的方法和组合物
WO2024243217A1 (en) 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025054320A1 (en) 2023-09-05 2025-03-13 Tizona Therapeutics Anti-ackr4 antibodies, compositions and uses thereof
WO2025054328A1 (en) 2023-09-05 2025-03-13 Tizona Therapeutics Bispecific binding construct capable of binding to ackr4, compositions comprising a bispecific binding construct capable of binding to ackr4, and methods of using bispecific binding construct capable of binding to ackr4
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies
WO2025080711A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Dual payload antibody drug conjugates
WO2025081117A2 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025109193A1 (en) 2023-11-24 2025-05-30 Sanofi Synthesized thiazolidines as a cysteine delivery method in cell culture feed
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
WO2025157132A1 (en) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
US20250250214A1 (en) 2024-02-07 2025-08-07 Braskem S.A. Method for dehydration of alcohol mixtures
WO2025199118A1 (en) 2024-03-18 2025-09-25 Willow Neuroscience, Inc. Anti-trem1 antibody constructs, compositions comprising anti-trem1 antibody constructs and methods of using anti-trem1 antibody constructs
WO2025210195A1 (en) 2024-04-03 2025-10-09 Institut Pasteur Apsab combines a nuclease/helicase protein and an argonaute-like protein to cleave dna
WO2025213047A1 (en) 2024-04-05 2025-10-09 Tizona Therapeutics, Inc. Anti-il-18bp antibodies, compositions comprising anti-il-18bp antibodies and methods of using anti-il-18bp antibodies
WO2025217101A2 (en) 2024-04-09 2025-10-16 Amgen Inc. Agonistic anti-il-2rbg heavy‑chain antibodies
WO2025240781A2 (en) 2024-05-15 2025-11-20 Werewolf Therapeutics, Inc. Modified antibodies and immunoglobulin formats
WO2025250831A1 (en) 2024-05-30 2025-12-04 Astellas Pharma Inc. Sting agonist immunostimulatory antibody drug conjugates
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2461379A1 (de) * 1974-01-11 1975-07-17 Anvar Verfahren zur herstellung von interferon in grossen mengen und in industriellem masstab
US3926723A (en) * 1974-08-08 1975-12-16 Massachusetts Inst Technology Method of controllably releasing glucose to a cell culture medium
WO1984000777A1 (en) * 1982-08-23 1984-03-01 Unisearch Ltd Production of secondary metabolites from micro organisms
JPS6054677A (ja) * 1983-09-05 1985-03-29 Agency Of Ind Science & Technol ヒトインタ−フェロン産生細胞の培養方法

Also Published As

Publication number Publication date
KR920010871B1 (ko) 1992-12-19
BG51050A3 (bg) 1993-01-29
EP0229809B1 (de) 1992-08-26
DK95687D0 (da) 1987-02-25
WO1987000195A1 (en) 1987-01-15
GB8704450D0 (en) 1987-04-01
DE3686572T2 (de) 1993-04-08
DK95687A (da) 1987-04-28
HU197042B (en) 1989-02-28
DE3686572D1 (de) 1992-10-01
RU2015164C1 (ru) 1994-06-30
GB2195655B (en) 1989-10-25
GB8516415D0 (en) 1985-07-31
CA1282360C (en) 1991-04-02
AU6134886A (en) 1987-01-30
GB2195655A (en) 1988-04-13
JPS62503146A (ja) 1987-12-17
KR880700062A (ko) 1988-02-15
HUT42522A (en) 1987-07-28
AU590600B2 (en) 1989-11-09
EP0229809A1 (de) 1987-07-29

Similar Documents

Publication Publication Date Title
ATE79900T1 (de) Tierzellenkultur.
DE60335024D1 (de) Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
ATE71137T1 (de) Fermentationsprozess und fermenter.
SE8500621L (sv) Forbettrad proteinframstellning med anvendning av hypertoniska medier
GB2196636B (en) Production of proteins by cell culture
NO882469D0 (no) Fremgangsmaate for produksjon av proteiner ved bruk av induserbare ekspresjonssystemer i genetisk modifiserte eukaryotiske vertsceller formert in vivo.
DE3485444D1 (de) Hybrid-dns-synthese von insulin.
ES8105384A1 (es) Procedimiento para la produccion de un material de proteina unicelular
ATE258594T1 (de) Verfahren zur steigerung des wachstums von pflanzenzellkulturen
GB1464939A (en) Process for the production of interferon
DE3479518D1 (en) Process for the multiplication of plant cell aggregates
GB1443948A (en) Production of immunological material
JPS6451079A (en) Serumfree medium for cultivation of human/human hybridoma
KR920012425A (ko) 동물세포 배양용 고농도 배지 및 배양공정
ATE97958T1 (de) Zellenzuchtverfahren fuer die produktion von aktiviertem protein-c.
SU1279236A1 (ru) Способ непрерывного культивирования дрожжей
Shirai et al. Energy Balance and Protein Synthesis in Hybridoma Culture
IT1196408B (it) Procedimento per coltura di streptococcus pyogenes emolitico
JPS54110384A (en) Culturing medium for humanized lymphocyte
EP0326537A3 (de) Verfahren zur Steigerung der Ausbeute an t-PA in Zellkulturen
GB976093A (en) Method for producing l-homoserine by fermentation process

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
RZN Patent revoked